COVID-19: Potassium Contributes to Pathologies that Cause Disability

Infect Disord Drug Targets. 2023;23(7):39-41. doi: 10.2174/1871526523666230529163610.

Ziad Fajloun^{1

2}, Yingliang Wu³, Zhijian Cao³, Hervé Kovacic⁴, Jean-Marc Sabatier⁴

¹ Department of Biology, Faculty of Sciences, Lebanese University, Campus Michel Slayman Ras Maska, 1352 Tripoli, Lebanon.
² Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and its Applications, EDST, Lebanese.
³ State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China.
⁴ Institute of NeuroPhysiopathology (INP), UMR 7051, Aix-Marseille University, Marseille 13385, France.

No abstract available

Keywords: AT1R receptor; COVID-19; Electrolyte; Hypokalemia; Long COVID; Potassium; RAS; SARS-CoV-2.

Publication types